Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses screening of various microvascular complications of type 2 diabetes and evaluates their cost-effectiveness.
Speaker’s Bureau: Merck, NovoNordisk, GSK
Advisory Panel: Merck, BMS, Astra Zeneca, Boehringer Ingelheim, Biodel
Consultant: Merck, Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories
Stock/Shareholder: Covidien, Bard, Novartis, Roche, Stryker